---
document_datetime: 2024-03-11 16:58:46
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/pramipexole-accord-epar-public-assessment-report_en.pdf
document_name: pramipexole-accord-epar-public-assessment-report_en.pdf
version: success
processing_time: 5.2052816
conversion_datetime: 2025-12-14 21:16:41.291083
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

London, 21 July 2011 EMA/816841/2011 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pramipexole Accord International nonproprietary name: pramipexole Procedure No.: EMEA/H/C/2291 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 8545

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. ............................................5 Background information on the procedure                                                                                                                                                                 | 1. ............................................5 Background information on the procedure                                                                                                                                                                 | 1. ............................................5 Background information on the procedure                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier.................................................................................... 5 1.2. Manufacturers ................................................................................................... 6 authorised | 1.1. Submission of the dossier.................................................................................... 5 1.2. Manufacturers ................................................................................................... 6 authorised | 1.1. Submission of the dossier.................................................................................... 5 1.2. Manufacturers ................................................................................................... 6 authorised |
| 1.3. Steps taken for the assessment of the product ....................................................... 7                                                                                                                                             | 1.3. Steps taken for the assessment of the product ....................................................... 7                                                                                                                                             | 1.3. Steps taken for the assessment of the product ....................................................... 7                                                                                                                                             |
| 2. ..............................................................................8 Scientific discussion                                                                                                                                                 | 2. ..............................................................................8 Scientific discussion                                                                                                                                                 | 2. ..............................................................................8 Scientific discussion                                                                                                                                                 |
| 2.1.                                                                                                                                                                                                                                                     | .................................................................................................... 8 Introduction                                                                                                                                      | .................................................................................................... 8 Introduction                                                                                                                                      |
| 2.2.                                                                                                                                                                                                                                                     | ................................................................................................ 9 Quality aspects                                                                                                                                       | ................................................................................................ 9 Quality aspects                                                                                                                                       |
| 2.2.1. Introduction                                                                                                                                                                                                                                      | 2.2.1. Introduction                                                                                                                                                                                                                                      | ............................................................................................... 9                                                                                                                                                        |
| 2.2.2. Active Substance                                                                                                                                                                                                                                  | 2.2.2. Active Substance                                                                                                                                                                                                                                  | ......................................................................................... 9                                                                                                                                                              |
| 2.2.3. Finished Medicinal                                                                                                                                                                                                                                | 2.2.3. Finished Medicinal                                                                                                                                                                                                                                | .......................................................................... 11 Product                                                                                                                                                                    |
| 2.2.4. Discussion on chemical and pharmaceutical                                                                                                                                                                                                         | 2.2.4. Discussion on chemical and pharmaceutical                                                                                                                                                                                                         | ....................................... 12 aspects                                                                                                                                                                                                       |
| 2.2.5. ................. Conclusions on the chemical, pharmaceutical and biological aspects longer                                                                                                                                                       | 2.2.5. ................. Conclusions on the chemical, pharmaceutical and biological aspects longer                                                                                                                                                       | 13                                                                                                                                                                                                                                                       |
| 2.3. ...................................................................................... 13 Non- Clinical aspects                                                                                                                                     | 2.3. ...................................................................................... 13 Non- Clinical aspects                                                                                                                                     | 2.3. ...................................................................................... 13 Non- Clinical aspects                                                                                                                                     |
| 2.3.1. Introduction..............................................................................................                                                                                                                                        | 2.3.1. Introduction..............................................................................................                                                                                                                                        | 13                                                                                                                                                                                                                                                       |
| 2.3.2. Ecotoxicity/environmental                                                                                                                                                                                                                         | 2.3.2. Ecotoxicity/environmental                                                                                                                                                                                                                         | .................................................... 13 risk assessment                                                                                                                                                                                  |
| 2.3.3. Conclusion on the non-clinical aspects                                                                                                                                                                                                            | 2.3.3. Conclusion on the non-clinical aspects                                                                                                                                                                                                            | .......................................................... 14                                                                                                                                                                                            |
| 2.4. .............................................................................................. Clinical Aspects                                                                                                                                     | 2.4. .............................................................................................. Clinical Aspects                                                                                                                                     | 14                                                                                                                                                                                                                                                       |
| 2.4.1. .............................................................................................. Introduction no                                                                                                                                    | 2.4.1. .............................................................................................. Introduction no                                                                                                                                    | 14                                                                                                                                                                                                                                                       |
| 2.4.2. ....................................................................................... Pharmacokinetics                                                                                                                                          | 2.4.2. ....................................................................................... Pharmacokinetics                                                                                                                                          | 15                                                                                                                                                                                                                                                       |
| 2.4.3. ..................................................................................... Pharmacodynamics                                                                                                                                            | 2.4.3. ..................................................................................... Pharmacodynamics                                                                                                                                            | 19                                                                                                                                                                                                                                                       |
| 2.4.4. Additional data                                                                                                                                                                                                                                   | 2.4.4. Additional data                                                                                                                                                                                                                                   | .......................................................................................... 19                                                                                                                                                            |
| 2.4.5. Post marketing experience                                                                                                                                                                                                                         | 2.4.5. Post marketing experience                                                                                                                                                                                                                         | .......................................................................... 19                                                                                                                                                                            |
| 2.4.6. Discussion                                                                                                                                                                                                                                        | 2.4.6. Discussion                                                                                                                                                                                                                                        | ...................................................................... 19 on Clinical aspects                                                                                                                                                            |
|                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                          | 19                                                                                                                                                                                                                                                       |
| 2.4.7. ..................................................................... Conclusions on clinical aspects product                                                                                                                                     | 2.4.7. ..................................................................... Conclusions on clinical aspects product                                                                                                                                     | 19                                                                                                                                                                                                                                                       |
| 2.5.                                                                                                                                                                                                                                                     | ......................................................................................... Pharmacovigilance                                                                                                                                              | ......................................................................................... Pharmacovigilance                                                                                                                                              |
| 2.6.                                                                                                                                                                                                                                                     | ........................................................................................... 20 User consultation                                                                                                                                         | ........................................................................................... 20 User consultation                                                                                                                                         |
| 3.                                                                                                                                                                                                                                                       | Recommendation.................................................................................20                                                                                                                                                        | Recommendation.................................................................................20                                                                                                                                                        |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of Abbreviations

PK - Pharmacokinetics alu - aluminium ASMF - Active Substance Master File AUC0-t - area under the plasma concentration versus time curve from time zero to the last measurable concentration AUC0-∞ - area under the plasma concentration versus time curve BE - Bioequivalence BMI - Body Mass Index CHMP - Committee for Medicinal Products for Human Use Cmax - Maximum measured plasma concentration 13 C-NMR - Carbon-13 Nuclear Magnetic Resonance DA - Dopamine EDTA - Ethylenediaminetetraacetic acid EMA - European Medicines Agency ERA - Environmental Risk Assessment FT-IR - Fourier Transform InfraRed GC - Gas Chromatography GCP - Good Clinical Practice 1 H-NMR - Proton (also Hydrogen-1) Nuclear Magnetic Resonance HPLC - High Performance Liquid Chromatography ICH - International Conference on Harmonisation LOD - Limit of detection LOQ - Limit of quantitation MAH - Marketing Authorisation Holder mg - milligram MS - Mass Spectroscopy Ph Eur - European Pharmacopoeia pKa - Acid dissociation constant (also acidity constant) Medicinal product no longer authorised

PD - Parkinson's disease

PSUR - Periodic Safety Update Report

RH - Relative Humidity

<div style=\"page-break-after: always\"></div>

<!-- image -->

Pramipexole Accord

Assessment report

EMA/816841/2011

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier



The  applicant  Accord  Healthcare  Ltd  submitted  on  1 November 2010  an  application  for  Marketing Authorisation to the European Medicines Agency (EMA) for Pramipexole Accord 0.088 mg, 0.18 mg, 0.35  mg,  0.7  mg  and  1.1  mg  tablets,  through  the  centralised  procedure  under  Article  3 (3)  of Regulation  (EC)  No.  726/2004  -  'Generic  of  a  Centrally  authorised  product'.  The  eligibility  to  the centralised procedure was agreed upon by the EMA/CHMP on 18 February 2010. The  application  concerns  a  generic  medicinal  product  as  defined  in  Article  10(2)(b)  of  Directive 2001/83/EC  and  refers  to  a  reference  product  for  which  a  Marketing  Authorisation  is  or  has  been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC. The applicant applied for the following indication: Pramipexole  Accord  is  indicated  in  adults  for  treatment  of  the  signs  and  symptoms  of  idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on off' fluctuations). Pramipexole Accord is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt). The legal basis for this application refers to the Article 10(1) of Directive 2001/83/EC. The  application  submitted  is  composed  of  administrative  information,  complete  quality  data  and  a bioequivalence study with the reference medicinal product Mirapexin instead of non-clinical and clinical data. The chosen reference product is: ■ Medicinal product which is or has been authorised in accordance with Community provisions in accordance with Community provisions in force for not less than 6/10 years in the EEA:  Product  name,  strength,  pharmaceutical  form: Mirapexin  0.088 mg,  0.18 mg,  0.35 mg, 0.7 mg, 1.1 mg tablets  Marketing authorisation holder: Boehringer Ingelheim International GmbH  Date of authorisation: 23-02-1998  Marketing authorisation granted by:  Community  Community Marketing authorisation number: EU/1/97/051/001-012 ■ Medicinal product authorised in the Community/Members State where the application is made or European reference medicinal product: Medicinal product no longer authorised

Product  name,  strength,  pharmaceutical  form: Mirapexin  0.088 mg,  0.18 mg,  0.35 mg, 0.7 mg, 1.1 mg tablets

-  Marketing authorisation holder: Boehringer Ingelheim International GmbH
-  Date of authorisation: 23-02-1998
-  Marketing authorisation granted by:

<div style=\"page-break-after: always\"></div>

##  Community

-  Community Marketing authorisation number: EU/1/97/051/001-012
- ■ Medicinal product which is or has been authorised in accordance with Community provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

<!-- image -->

 Product name, strength, pharmaceutical form: Mirapexin 0.18 mg tablets  Marketing authorisation holder: Boehringer Ingelheim International GmbH  Date of authorisation: 23-02-1998  Marketing authorisation granted by:  Community  Community Marketing authorisation numbers: EU/1/97/051/003-004  Bioavailability study number: 245-07 Scientific Advice The applicant did not seek scientific advice at the CHMP. Licensing status The product was not licensed in any country at the time of submission of the application. 1.2. Manufacturers Manufacturer responsible for batch release Accord Healthcare Ltd. Sage House 319 Pinner road North Harrow, Middx HA1 4HF United Kingdom Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1.3. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was Eva Skovlund

<!-- image -->

applicant. The final consolidated List of Questions was sent to the applicant on submitted the responses to the CHMP  consolidated List of Questions on rt  on  the  applicant's  responses  to  the  List  of the CHMP agreed on a list of outstanding issues to ort on the applicant's responses to the outstanding a  positive opinion for granting a Marketing Authorisation to Pramipexole Accord on 21 July 2011.  The application was received by the EMA on 1 November 2010.  The procedure started on 17 November 2010.  The Rapporteur's first Assessment Report was circulated to all CHMP members on 4 February 2011.  During the meeting on 14-17 March 2011, the CHMP agreed on the consolidated List of Questions to be sent to the 18 March 2011.  The applicant 21 April 2011.  The  Rapporteur  circulated  the  Assessment  Repo Questions to all CHMP members on  1 June 2011.  During the CHMP meeting on 20-23 June 2011, be addressed in writing by the applicant.  The applicant submitted the responses to the CHMP list of outstanding issues on 27 June 2011.  The Rapporteur circulated the Assessment Rep issues to all CHMP members on  7 July 2011.  During the meeting on 18-21 July 2011, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Pramipexole  Accord  0.088 mg,  0.18 mg,  0.35 mg,  0.7 mg,  1.1  mg  tablets  is  a  generic  medicinal product  containing  pramipexole,  in  form  of  the  dihydrochloride  monohydrate  salt,  as  the  active substance. Pramipexole is administered orally. Pramipexole is a synthetic amino-benzothiazole derivative. It has been shown to be a selective and specific full DA receptor agonist with high affinity and selectivity for the DA D2 receptor subfamily, and particularly the D3 receptor subtype. Pramipexole is a non-ergot dopamine agonist with actions similar to those of bromocriptine. It is used in the management of Parkinson's disease, alone or as an adjunct to levodopa therapy in more advanced stages of the disease. Pramipexole is also indicated in adults for symptomatic  treatment  of  moderate  to  severe  idiopathic  Restless  Legs  Syndrome  in  doses  up  to 0.54 mg of base (0.75 mg of salt). The efficacy and safety of pramipexole has been demonstrated in randomised, placebo-controlled and comparative trials. A summary of these studies may be found in the EPAR for Mirapexin. The indication  of  Pramipexole Accord  is  the  same  as  authorised  for  the  reference  medicinal  product Mirapexin.  Mirapexin  is  indicated  in  adults  for  treatment  of  the  signs  and  symptoms  of  idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations  of  the  therapeutic  effect  occur  (end  of  dose  or  'on  off'  fluctuations).  Mirapexin  is  also indicated  in  adults  for  symptomatic  treatment  of  moderate  to  severe  idiopathic  Restless  Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt). Parkinson's  disease  (PD)  is  a  neurodegenerative  disorder  characterised  by  bradykinesia,  rigidity, postural imbalance and tremor. The incidence of PD increases with age and on average, 2 to 3 % of the  population  in  the  western  world  will  develop  PD.  The  cause  of  the  disease  is  still  unknown.  PD develops due to loss of  neuronal  functions  within the  basal  ganglia  and  the  substantia  nigra  of  the brain. More specifically, there is a marked deficiency in the nigrostriatal dopamine (DA) system due to degeneration  of  nigral  DA  neurons.  Thus,  restoration  of  the  dopaminergic  transmission  forms  the central strategy for the treatment of PD. Restless Legs Syndrome (RLS) is a neurological sensory-motor disorder characterised by four essential diagnostic criteria defined by the International Restless Legs Syndrome Study Group (IRLSSG) in 1995 and  updated  in  2003,  with  an  estimated  prevalence  in  the  general  population  of  2.5%  to  15%. Dopamine  agonists,  including  pramipexole,  were  regarded  as  first  line  treatment  in  'Principles  and Practice of Sleep Medicine'. Mirapexin  was  authorised  through  the  centralised  procedure  and  therefore  the  qualitative  and quantitative  composition  of  the  active  substance  [pramipexole  in  form  of  the  dihydrochloride monohydrate  salt]  and  the  excipients  [mannitol,  maize  starch,  anhydrous  colloidal  silica,  povidone, magnesium stearate] is identical in all Member States. The formulation of Pramipexole Accord tablets differs  namely  by  the  inclusion  of  microcrystalline  cellulose  which  is  not  present  in  the  reference medicinal product. Medicinal product no longer authorised

The  bioequivalence  has  been  studied  only  with  the  0.18 mg  strength  and  for  other  strengths  a biowaiver was claimed.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1.   Introduction

<!-- image -->

Pramipexole  Accord  is  presented  as  tablets  containing  pramipexole,  in  form  of  the  dihydrochloride monohydrate salt, as the active substance. Tablets contain 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg or 1.1 mg of pramipexole which is an equivalent of respectively 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg and 1.5 mg of the salt. The tablets are white to off-white, round, flat faced, bevel edged and differentiated by presence of a breakline and appropriate bossing:  0.088 mg tablets: inscription 'I1' on one side and are plain on the other side  0.18 mg tablets: inscription 'I' and '2' on either side of the breakline on one side and breakline on the other side  0.35 mg tablets: inscription 'I' and '3' on either side of the breakline on one side and breakline on the other side  0.7 mg tablets: inscription 'I' and '4' on either side of the breakline on one side and breakline on the other side  1.1 mg tablets: inscription 'I' and '5' on either side of the breakline on one side and breakline on the other side Excipients  used  in  the  preparation  of  Pramipexole  Accord  tablets  are  well  known  excipients  such  as mannitol, maize starch, anhydrous colloidal silica, povidone, magnesium stearate and microcrystalline cellulose. Pramipexole Accord tablets are packed in aluminium (alu/alu) blisters. 2.2.2.   Active Substance Pramipexole dihydrochloride monohydrate, the active substance, is chemically designated as (6S)-6N -propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine  dihydrochloride  monohydrate,  and  has  the following structure: Pramipexole dihydrochloride  monohydrate  is  a  white  or  almost  white  crystalline  powder.  It  is  freely soluble  in  water,  soluble  in  methanol,  slightly  soluble  in  ethanol  (96%)  and  practically  insoluble  in methylene chloride. Its pKa is 7.2 and pH is 2.8 to 3.4. The molecule has one chiral center and exhibits isomerism. In the manufacture of Pramipexole Accord tables, the same as for the reference medicinal product, the S-enantiomer is used. Manufacture Medicinal product no longer authorised

Information about manufacturing process has been provided using the Active Substance Master File (ASMF) procedure. The active substance is synthesised in a two step synthesis followed by the salt formation  and  purification  step.  Detailed  description  of  the  manufacturing  process  was  provided.

<div style=\"page-break-after: always\"></div>

Critical  parameters  and  accompanying  in-process  controls,  to  ensure  quality  of  the  final  compound, have been defined and are controlled.

Confirmation of the chemical structure of pramipexole dihydrochloride monohydrate was provided by elemental analysis (confirmation of the determined elementary composition), spectroscopic methods as UV, FT-IR, 1 H-NMR,  13 C-NMR and MS (mass spectra). Also the physicochemical characteristics such us polymorphism,  solubility,  pKa  and  pH  have  been  investigated.  Polymorphism  was  studied  using  the X-ray diffraction.

Forced  degradation  studies  showed  that  pramipexole  dihydrochloride  monohydrate  is  stable  under exposure to elevated temperatures (heat), humidity (including in the dissolved state) and light. The results  were  also  within  specifications  after  exposure  to  acid  or  alkaline  conditions.  Under  oxidative conditions an unknown impurity was observed.

Pramipexole dihydrochloride monohydrate was analyzed using the Ph Eur HPLC method to identify all potential  impurities.  Impurities  have  been  well  characterised  in  relation  to  their  origin  and  potential carry-over into the final drug substance. Chemical names, structure, limit of detection (LOD) and limit of quantitation (LOQ) along with their limits in the release specifications have been described. Other impurities which were observed at minor concentrations are also controlled at a level of 0.10% under Maximum Single Unknown Impurities and Total Impurities at a level of 0.50%. As the below mentioned impurities are specified in the Ph Eur monograph, the structural elucidation for the same has not been provided. Specification The  active  substance  specification  includes  tests  for  appearance,  solubility,  appearance  of  solution, identification  (IR),  specific  optical  rotation,  presence  of  chlorides,  pH,  related  substances  (HPLC), enantiomeric  purity  (HPLC),  heavy  metals,  water  content,  sulphated  ash,  assay  (potentiometric titration), bioburden, residual solvents (GC), HCl content and  particle size distribution (laser diffraction).  The  specification  generally  complies  with  the  Ph  Eur  monograph  for  pramipexole  with additional in-house tests for which suitable validation data are provided. A detailed description for all analytical methods was provided. Most of the methods are Ph Eur apart from particle size, HCl content and residual solvents. Full method validation data was provided for the non compendial (in-house) analytical methods. In general analytical methods proposed are suitable to control the quality of the drug substance. Data  on  four  batches  of  the  active  substance,  used  in  the  manufacture  of  the  product  used  for validation, bioequivalence (BE) and stability study have been presented. Results for all these batches were provided by both the active substance and the finished product manufacturers. In addition results for three recently manufactured batches were provided. Certificates of analyses for the active substance were provided and all batch analysis results comply with the specifications and show a good uniformity from batch to batch. Stability Stability  studies  were  performed  for  the  first  three  validation  batches  in  accordance  with  the  ICH requirements under the following conditions: 40°C ± 2°C/75 ± 5% RH (accelerated), 30 ± 2°C/65% ± 5% RH  (intermediate)  and  25 ± 2°C/60% ± 5% RH  (long  term  -  real  time).  Data obtained cover period of 5 years at long-term conditions and 6 months at accelerated conditions. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Results obtained from the stability studies demonstrated adequate stability of the active substance and confirmed the proposed re-test period.

## 2.2.3.   Finished Medicinal Product

Pharmaceutical Development The  aim  of  the  pharmaceutical  development  was  to  obtain  immediate  release  tablets,  containing quantitatively and qualitatively the same active substance as the reference medicinal product, and to be bioequivalent. Similarity with Mirapexin tablets was addressed by way of composition comparisons, dissolution studies, solubility studies and comparative impurity profiles. Compositions  of  Pramipexole  Accord  tablets  and  the  reference  medicinal  product  are  similar.  The formulation of Pramipexole Accord tablets contain the same excipients as Mirapexin, and differ only by the presence of microcrystalline cellulose which is not used in the reference medicinal product. Similarity  between  Pramipexole  Accord  and  the  reference  product  was  also  shown  by  dissolution testing. Comparative dissolution profiles of Pramipexole Accord 0.18 mg tablets and reference product Mirapexin 0.18 mg tablets, and Pramipexole Accord 0.18 mg tablets and other strengths of Pramipexole Accord tablets, in three different media: 0,1 M HCl, acetate buffer pH 4,5 and phosphate buffer  pH 6,8  have  been  conducted.  The  dissolution  profiles  of  the  test  product  and  the  reference product were considered similar in all three media. An  impurity  comparison  of  Pramipexole  Accord  and  the  reference  product  was  undertaken.  Results showed no degradation to occur as a result of the manufacturing process as the impurity profile for the generic product was similar to that of the product. The  application  concerns  five  strengths  however  the  bioequivalence  was  demonstrated  between Pramipexole Accord 0.18 mg tablets and Mirapexin 0.18 mg tablets, and a biowaiver for the 0.088 mg, 0.35 mg, 0.7 mg and 1.1 mg strengths was claimed. The biowaiver could be applied since:  other strengths are manufactured by the same manufacturer and process,  the drug input has been shown to be linear over the therapeutic dose range,  the qualitative composition of the strengths is the same; the amount of the active substance is less than 5 % of the tablet weight and amounts of different excipients are the same for all the concerned strengths and only the amount of active substance is changed.  the ratio between amounts of active substance and excipients is the same,  dissolution profiles of the additional strengths and the strength used in the bioequivalence study were similar under identical conditions The  reference  product  is  presented  as  uncoated  tablets  therefore  Pramipexole  Accord  was  also developed as uncoated tablets. Medicinal product no longer authorised

<!-- image -->

Different  formulations  were  prepared  and  studied  during  the  development  program.  A  formulation optimisation  study  was  performed  regarding  the  effects  of  the  concentration  of  excipients.  The selection  of  excipients  was  based  not  only  on  the  reference  product  but  also  on  the  results  from laboratory  scale  formulations.  The  final  formulation  was  chosen  based  on  the  results  from  these studies.

Different technological processes such as direct tabletting and wet granulation were tested during the development. Direct compression was selected as the final manufacturing process.

<div style=\"page-break-after: always\"></div>

## Adventitious agents

None of the excipients used in the drug product are of animal origin. Magnesium stearate used in the formulation is of vegetal origin.

Manufacture of the product The proposed manufacturing process is dry, direct-compression. This standard manufacturing process has been sufficiently characterised and includes weighing, sieving, mixing by co-sifting procedure and compressing as steps during manufacture. A flow diagram and detailed description of the manufacturing  process  have  been  provided.  The  critical  steps  and  in-process  controls  have  been identified.  Process  validation  has  been  carried  out  on  three  consecutive  batches  for  all  strengths  of Pramipexole Accord. The batch analysis results show that the medicinal product can be manufactured reproducibly according the agreed finished product specifications. Product Specification The product specification is standard for tablets and contains tests with suitable limits for appearance (description),  average  weight  of  tablets,  identification  (HPLC  and  UV),  disintegration  time,  friability, resistance  to  crushing,  water  content  by  loss  on  drying,  dissolution,  uniformity  of  dosage  units  (by content  uniformity),  related  substances  (HPLC),  assay  (HPLC),  subdivision  of  tablets  and  microbial limits. Full details of all analytical methods have been provided. All non pharmacopoeial methods have been satisfactory validated. The HPLC methods used for assay, dissolution, content uniformity and related substances have been validated in accordance with ICH requirements. As part of method validation, stress studies (UV light, heat, water/acid/base hydrolysis and oxidation) were performed to provide an indication of the stability-indicating properties and specificity of the HPLC method. Batch analysis data was provided on three production scale batches of each strength. Batches met the proposed specification limits. Results showed that tablets can be manufactured reproducibly according to the finished product specifications. Stability of the product Stability  studies  were  carried  out  under  ICH  conditions  of  25ºC/60% RH  (long  term),  30ºC/65% RH (intermediate) and 40ºC/75% RH (accelerated) on three production scale batches each of Pramipexole Accord tablets. Based on the stability data the proposed shelf-life and storage conditions as defined in the SmPC are acceptable. In summary the stability data provided support the proposed shelf-life and storage conditions. 2.2.4.   Discussion on chemical and pharmaceutical aspects Information about the active substance, pramipexole dihydrochloride monohydrate, has been provided using the Active Substance Master File Procedure. The chemical-pharmaceutical documentation was of acceptable quality. Medicinal product no longer authorised

The  active  substance  has  been  satisfactorily  characterized  and  the  synthesis  is  well  controlled. Pramipexole  dihydrochloride  monohydrate  is  highly  soluble  and  highly  permeable,  therefore  was classified  as  BCS  class  1  active  substance.  Known  and  potential  impurities  have  been  satisfactorily

<div style=\"page-break-after: always\"></div>

addressed. The control tests and specifications for the active substance are in line with the ICH and Ph Eur and are considered satisfactory. A retest period was supported by satisfactory stability studies that show that the active substance is stable in solid form.

The finished product is an immediate release tablet containing 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg or 1.1 mg  of  pramipexole  in  form  of  the  dihydrochloride  monohydrate  salt.  The  composition  of  the finished product has been described, and all excipients have been fully characterised. The  applicant  has  demonstrated  that  Pramipexole  Accord  is  bioequivalent  to  the  reference  product Mirapexin.  The  development  pharmaceutics  has  been  satisfactorily  described  and  the  formulation  is considered  satisfactorily  justified.  The  method  of  manufacture  is  considered  standard  and  has  been satisfactorily  described.  Process  validation  has  been  carried  out  on  three  consecutive  batches  for  all strengths of Pramipexole Accord. The  batch analysis results show  that the product can be manufactured reproducibly according the agreed finished product specifications. The scope of the finished product specification complies with ICH Q6A and the Ph Eur requirements for tablets,  limits  comply  with  regulatory  requirements  and  are  in  line  with  batch  data.  The  analytical methods and validation data are satisfactory. The  stability  program  is  considered  satisfactory.  The  results  generated  during  the  stability  studies support the proposed shelf life and storage conditions as defined in the SmPC. 2.2.5.   Conclusions on the chemical, pharmaceutical and biological aspects Information on development, manufacture and control of the active substance and the finished product has  been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried out indicate that physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. 2.3. Non- Clinical aspects 2.3.1. Introduction A  non-clinical  overview  on  the  pharmacology,  pharmacokinetics  and  toxicology  has  been  provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need  to  generate  additional  non-clinical  pharmacology,  pharmacokinetics  and  toxicology  data.  The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. 2.3.2.   Ecotoxicity/environmental risk assessment No Environmental Risk Assessment (ERA) was submitted. This was justified by the applicant as the introduction of Pramipexole Accord manufactured by Accord Healthcare Limited is considered unlikely to  result  in  any  significant  increase  in  the  combined  sales  volumes  for  all  pramipexole  containing products and the exposure of the environment to the active substance. Thus, the ERA is expected to be similar and not increased. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.3.3. Conclusion on the non-clinical aspects

There is  no  need  to  generate  additional  non-clinical  pharmacology,  pharmacokinetics  and  toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The CHMP agreed that no further non-clinical studies are required.

<!-- image -->

2.4. Clinical Aspects 2.4.1.   Introduction This is an application for tablets containing pramipexole dihydrochloride monohydrate. To support the marketing authorisation application the applicant conducted one bioequivalence study with cross-over design under fasting conditions. This study was the pivotal study for the assessment. No  formal  scientific  advice  by  the  CHMP  was  given  for  this  medicinal  product.  For  the  clinical assessment Guideline  on  the  Investigation  of  Bioequivalence  CPMP/EWP/QWP/1401/98  Rev.1 in  its current version is of particular relevance. GCP The Clinical trials were performed in accordance with GCP as claimed by the applicant The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC. Exemption This application concerns 5 strengths of pramipexole dihydrochloride  monohydrate;  0.125 mg (=0.088 mg  pramipexole), 0.25 mg  (=0.18 mg  pramipexole), 0.5 mg  (=0.35 mg  pramipexole), 1.0 mg  (=0.7 mg  pramipexole)  and  1.5 mg  (=1.1 mg  pramipexole)  but  bioequivalence  has  been studied  with  the  0.25  mg  strength  only.  The  applicant  has  applied  for  a  biowaiver  for  the  tablet strengths of 0.125 mg, 0.5 mg, 1.0 mg and 1.5 mg. According to the Guideline on the Investigation of Bioequivalence  (CPMP/EWP/QWP/1401/98 Rev. 1/Corr**), there are general biowaiver criteria that should be fulfilled. For the current application, all of the conditions of the requirements in the Bioequivalence guideline for a biowaiver are considered fulfilled for all strengths. In conclusion, the CHMP considered a biowaiver for the additional strengths acceptable. Clinical studies To support the application, the applicant has submitted one bioequivalence study performed with the 0.25 mg (=0.18 mg pramipexole base) strength. Since this is a generic application, no further clinical studies are required and the applicant provides none. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.4.2.   Pharmacokinetics

## Methods

Study design Project  no.  245-07  was  an  open-label,  balanced,  randomised,  two-treatment,  two-period,  twosequence,  single  oral  dose,  crossover  bioequivalence  study  in  healthy  male  subjects  under  fasting conditions. Either a single dose of 0.25 mg (0.18 mg pramipexole base) of Pramipexole dihydrochloride tablets or Mirapexin  0.18  mg  tablets  was  administered  to  each  subject  with  240  ml  of  water  following  an overnight  fast  of  at  least  10  hours.  Dinner  was  served  approximately  10  hours  before  dosing.  Four hours after dosing snacks and meals were provided to the subjects at appropriate times. Blood sampling was performed pre-dose and at 0.5, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.50, 2.75, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 20, 24, 48 and 72 hours following the drug administration in each period. The wash out period was 7 days. The study was performed at Lambda Therapeutic Research Ltd, Navi Mumbai, Maharashtra, India. The bioanalysis  facility  was  located  in  India.A  statement  of  GCP  compliance  from  the  study  centre  was submitted. Test and reference products Pramipexole  dihydrochloride  0.25  mg  tablets  (0.18  mg  pramipexole  base)  manufactured  by  Intas Pharmaceuticals  Limited,  India  (Batch  No.  L01436,  exp.  date  01/2012)  has  been  compared  to Mirapexin 0.18 mg tablets manufactured by Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Germany (Batch No: 905343, exp. date 06/2012). Population studied Healthy, non smoking, Indian, male, adult volunteers aged between 18-55 years (mean age 26 years), having a Body Mass Index (BMI) between 18.5-24.9 kg/m 2  (mean BMI 22 kg/m 2 ) and having given their voluntary written informed consent, were enrolled in the study. They did not have any significant diseases  or  clinically  significant  abnormal  findings  in  any  of  the  screening  procedures  carried  out. Volunteers who complied with all the inclusion and none of the exclusion criteria were enrolled into the study. No female subjects were included in the trial. According to the applicant, the subject population for the bioequivalence study was selected with the aim to minimize variability and permit detection of differences  between  pharmaceutical  products,  and  therefore  the  study  was  performed  with  healthy males only. The subjects were not allowed to take any medicine within 14 days prior to dosing. Subjects had to abstain from consumption of grapefruits or its products within a period of 48 hours prior to dosing. In addition the subjects had to abstain from any xanthine containing food or beverages (like chocolate, tea, coffee or cola drinks), tobacco and tobacco containing products for 24 hours prior to dosing and throughout the stay in the clinical facility. Alcohol and alcoholic products, cigarettes and recreational drugs were not allowed until the last PK sample was taken. Medicinal product no longer authorised

<!-- image -->

A  total  of  30  subjects  were  checked-in  for  the  study.  Of  these,  28  subjects  were  randomised  to treatment. Two subjects were extra subjects and they were not dosed.

A total of 28 subjects were dosed in period I and 25 subjects completed the study.

<div style=\"page-break-after: always\"></div>

3 subjects did not report for period II check-in due to personal reasons. They were considered to be discontinued from the study on their own accord. These subjects were therefore not included in the efficacy analysis.

## Protocol deviations:

Samples were not collected within ±02 minutes of scheduled time for 4 subjects in period I and for 2 subjects in period II (these two were also two of the four in period I). The deviation varied from 7 to 260 minutes. The time points concerned were at 48 hours (2 subjects) and at 72 hours (4 subjects). The reason for the deviations was late arrival of the subjects. Actual time points were used for the pharmacokinetic and statistical evaluations. Ambulatory samples were not collected for 3 subjects (at time point 72 hours) in period I (one of these subjects  were  later  excluded  from  the  study  because  he  did  not  show  up  for  period  II)  and  for  1 subject  (at  time  point  48  hours)  in  period  II.  The  reason  for  these  missing  samples  was  that  the subjects did not show up. Missing samples were denoted as 'M' in the statistical analysis. One subject in period I did not refrain from drinking water till 2 hours after dosing. He was given ice cubes to suck to treat his adverse event (nausea). Two subjects in period I did not follow the posture restriction deviation (to be in sitting or ambulatory posture for  3  hours  post  dose).  They  were  allowed  to  lie  down  due  to  adverse  events  (nausea  and dizziness). The CHMP considered that the choice of population was acceptable, and that the protocol deviations most probably did not affect the study results. Analytical methods Plasma  samples  (containing  K2EDTA  as  anticoagulant)  obtained  in  the  bioequivalence  study  were analysed for pramipexole by a validated LC/MS/MS analytical method as per in house procedures. Sample analysis was conducted at Lambda Therapeutic Research Ltd., India to determine the plasma concentration of pramipexole in the study sample. The long-term freezer stability for pramipexole has been established for 589 days at -65 o C + 10 o C and covers the study sample storage period of twenty six (26) days. A total of 1147 plasma samples were analysed. In total 25 samples (2.2%) were reanalysed due to the following  reasons:  11  were  repeated  due  to  unidentified  processing  error,  7  were  repeated  due  to significant  variation  in  response  of  internal  standard,  6  were  repeated  due  to  low  calibration  curve standard was eliminated, 1 was repeated due to anomalous concentration. Pharmacokinetic Variables Primary Parameters: · Maximum measured plasma concentration (Cmax) · The area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t) Medicinal product no longer authorised

<!-- image -->

- The area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞ )

## Secondary Parameters:

- Time of maximum measured plasma concentration (Tmax)
- First order rate constant associated with the terminal (log -linear) portion of the curve ( λ z)

<div style=\"page-break-after: always\"></div>

- The elimination or terminal half-life (t 1/2 )
- % of residual area (AUC\\_% Extrap\\_obs)

The  pharmacokinetic  parameters  were  calculated  by  non-compartmental  model  using  WinNonlin Professional Software Version-5.0.1 (Pharsight Corporation, USA).

Statistical  comparison  of  the  pharmacokinetic  parameters  of  the  two  formulations  was  carried  out using PROC MIXED of SAS® Release 9.1.3 (SAS Institute Inc., USA) to assess the bioequivalence of both the formulations. The CHMP considered that the choice of the primary pharmacokinetic variables and non-compartmental method was acceptable. Statistical methods Dataset for the estimation of pharmacokinetic parameters was prepared using WinNonlin Professional Software (Version 5.0.1) for pramipexole. Estimation of pharmacokinetic parameters was also carried out using the same software. Descriptive statistics of the pharmacokinetic parameters were calculated and reported for pramipexole. Statistical analysis was performed on the data obtained by assaying the pramipexole content in plasma samples using SAS® Release 9.1.3 (SAS Institute Inc., USA). The comparison of the pharmacokinetic parameters was carried out using PROC MIXED of SAS® Release 9.1.3 (SAS Institute Inc., USA). Analysis of variance was carried out by employing PROC MIXED of SAS® Release 9.1.3 (SAS Institute Inc.,  USA)  for  un-transformed  and  ln-transformed  pharmacokinetic  parameters  Cmax,  AUC0-t  and AUC0-∞ for pramipexole. ANOVA model included Sequence, Formulation and Period as fixed effects and Subject (Sequence) as a random  effect.  Sequence  effect  was  tested  using  Subject  (Sequence)  as  error  term.  An  F-test  was performed to determine the statistical significance of the effects involved in the model at a significance level of 5% (alpha=0.05). Two one-sided tests for bioequivalence and 90% confidence intervals for the ratio  of  the  least  squares  means  between  the  test  and  reference  formulations  were  calculated  for untransformed and ln-transformed data of Cmax, AUC0-t and AUC0-∞ for pramipexole. The power of test to detect 20% difference between test and reference formulations was computed and reported for untransformed and ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ for pramipexole. Ratio of least squares means of test and reference formulation was computed for untransformed and ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ of pramipexole. Ratio analysis was reported for un-transformed and ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ for pramipexole. To be considered bioequivalent, the 90% confidence intervals of Cmax, AUC0-t and AUC0-∞ had to fall within an acceptance range of 80-125%. The  CHMP  considered  that  the  statistics  had  been  adequately  described  and  the  methods  were considered acceptable. Results Medicinal product no longer authorised

The pharmacokinetic parameters for the test and reference products are shown in Table 1.

<div style=\"page-break-after: always\"></div>

Table 1. Pharmacokinetic parameters (non-transformed values; arithmetic mean ± SD, tmax   median, range)

<!-- image -->

| Treatment                                                                                                                              | Treatment                                                                                                                       | AUC 0-t xg/ml/h                                                                                                                 | AUC 0- ∞ xg/ml/h                                                                                                                | C max xg/ml                                                                                                                     | t max h                                                                                                                         | T 1/2 h                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Test                                                                                                                                   | Test                                                                                                                            | 5590.67±97 6.88                                                                                                                 | 6257.81±11 63.60                                                                                                                | 519.00±84.43                                                                                                                    | 2.50 (1.00- 5.00)                                                                                                               | 7.072±1.20                                                                                                                      |
| Reference                                                                                                                              | Reference                                                                                                                       | 5627.68±91 5.05                                                                                                                 | 6283.40±10 57.73                                                                                                                | 525.88±94.41                                                                                                                    | 2.25 (1.50- 6.00)                                                                                                               | 7.031±0.84                                                                                                                      |
| *Ratio (90% CI)                                                                                                                        | *Ratio (90% CI)                                                                                                                 | 99.4 (97.16- 101.74)                                                                                                            | 99.5 (97.32- 101.77)                                                                                                            | 98.9 (95.19- 102.86)                                                                                                            | -                                                                                                                               | -                                                                                                                               |
| CV (%)                                                                                                                                 | CV (%)                                                                                                                          | 4.7%                                                                                                                            | 4.6%                                                                                                                            | 7.9%                                                                                                                            | -                                                                                                                               | -                                                                                                                               |
| AUC 0- ∞ area under the plasma AUC 0-t area under the plasma C max maximum plasma T max time for maximum concentration T 1/2 half-life | concentration-time curve from time zero to infinity concentration-time curve from time zero to t hours concentration authorised | concentration-time curve from time zero to infinity concentration-time curve from time zero to t hours concentration authorised | concentration-time curve from time zero to infinity concentration-time curve from time zero to t hours concentration authorised | concentration-time curve from time zero to infinity concentration-time curve from time zero to t hours concentration authorised | concentration-time curve from time zero to infinity concentration-time curve from time zero to t hours concentration authorised | concentration-time curve from time zero to infinity concentration-time curve from time zero to t hours concentration authorised |

AUC0-∞ area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration T1/2 half-life *ln-transformed values The  CHMP  concluded  that  bioequivalence  between  the  test and  reference product  has  been appropriately  shown.  The  90%  confidence  intervals  for  the  ln-transformed  C max ,  AUC0-t and  AUC0-∞ were within the acceptance range of 80-125%. The randomization scheme was considered appropriate. AUC0-t derived from the measurements was covering 80% or more of the AUC0-∞ for all the subjects included, demonstrating that the 72 hours sampling time was sufficient to estimate the bioavailability of pramipexole. No pre-dose levels of pramipexole were detected in any subjects, showing that the wash-out period was long enough to avoid any carry-over effects. According to the applicant, formulation, sequence and period effects for ln-transformed data for Cmax and AUC0-∞ were found to be statistically insignificant. For AUC0-t the formulation and sequence effects for  the  ln-transformed  data  were  also  statistically  insignificant,  however  the  period  effect  was statistically  significant  (p=0.0247). The MAH provided an acceptable explanation for this finding and the issue was considered to be resolved. For  the  sampling  points  48  and  72  hours,  all  plasma  samples  for  all  subjects  were  below  limit  of quantification. For one subject the plasma sample was below limit of quantification for the sample point 24 hours. No samples were above the limit of quantification. Safety data There  were  no  deaths,  serious  or  significant  adverse  events.  Two  subjects  reported  a  total  of  two adverse  events  during  the  course  of  the  study.  Both  adverse  events  (nausea  and  dizziness)  were reported  after  receiving  the  reference  product.  They  were  considered  possibly  related  to  the administered medicinal product, mild in nature and both resolved. No adverse events were reported for the test product. Medicinal product no longer authorised

Upon conclusion of the clinical portion of the study, the results from all subjects, who completed poststudy procedures including laboratory tests and vital signs measurements confirmed the absence of significant changes in the subjects' state of health.

<div style=\"page-break-after: always\"></div>

## Conclusions

Based  on  the  presented  bioequivalence  study  Pramipexole  Accord  is  considered  bioequivalent  with Mirapexin.

The results of Study Project no. 245-07 with the 0.18 mg formulation can be extrapolated to the other applied strengths (0.088 mg, 0.35 mg, 0.7 mg and 1.1 mg), according to conditions in Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 1/Corr**). 2.4.3.   Pharmacodynamics No  new  pharmacodynamic  studies  were  presented  and  no  such  studies  are  required  for  this application. 2.4.4.   Additional data Not applicable. 2.4.5.   Post marketing experience No post-marketing data are available. The medicinal product has not been marketed in any country. 2.4.6.   Discussion on Clinical aspects The CHMP assessment addressed pharmacokinetic data for a single bioequivalence study (Project no. 245-07).  One  single  dose  bioequivalence  study  is  considered  acceptable  as  the  product  is  an immediate release formulation. The CHMP considered the design of the study to be acceptable. The sampling period of 72 hours is considered sufficient, and the wash-out period of 7 days is long enough to avoid any carry-over effect to the second period. The CHMP considered the analytical method used in  the  bioequivalence study to be acceptable. The study was conducted in line with GCP. The CHMP considered that bioequivalence between the test and reference product has been appropriately shown. The  90%  confidence  intervals  for  the  ln-transformed  Cmax,  AUC0-t and  AUC0-∞ were  within  the acceptance range of 80-125%. 2.4.7.   Conclusions on clinical aspects Based  on  the  presented  bioequivalence  study,  Pramipexole  Accord  0.18  mg  tablet  is  considered bioequivalent with Mirapexin 0.18 mg tablet. 2.5. Pharmacovigilance Detailed description of the Pharmacovigilance system The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements. Risk Management Plan Medicinal product no longer authorised

The CHMP did not require the applicant to submit a Risk Management Plan (RMP) because in general, it is accepted that RMPs are not required for generic products unless a safety concern requiring additional risk minimisation activities has been identified for the reference medicinal product. There is an RMP in place for Mirapexin, but there are no additional risk minimisation activities implemented except routine

<div style=\"page-break-after: always\"></div>

activities in the form of information in the SmPC/PIL and labelling. The applicant has included in the proposed SmPC the information specified in the RMP of the reference product. At the request of the CHMP, the applicant has included also the changes resulting from variation application EMEA/H/C/xxxx/WS/0041/G which concerned an update of section 4.8 and other sections of the SmPC for the reference product. The CHMP considered the updated SmPC to be acceptable.

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that  the  benefit-risk  balance  of  Pramipexole  Accord  in  the  treatment  of  Parkinson's  disease  and moderate to severe idiopathic Restless Legs Syndrome is favourable and therefore recommends the granting of the marketing authorisation subject to the following conditions:

The CHMP, having considered the data submitted, was of the opinion that routine pharmacovigilance was adequate to monitor the safety of the product. 2.6. User consultation No full user consultation with target patient groups on the package leaflet has been performed on the basis  of  a  bridging  report  making  reference  to  Mirapexin.  The  bridging  report  submitted  by  the applicant has been found acceptable. 3. Benefit-Risk Balance This application concerns a generic version of pramipexole dihydrochloride monohydrate tablets. The reference product Mirapexin is indicated for the treatment of idiopathic Parkinson's disease and for the symptomatic  treatment  of  moderate  to  severe  idiopathic  Restless  Legs  Syndrome.  No  nonclinical studies  have  been  provided  for  this  generic  application  but  an  adequate  summary  of  the  available nonclinical  information  for  the  active  substance  was  presented  and  considered  sufficient.  From  a clinical  perspective,  this  application  does  not  contain  new  data  on  the  pharmacokinetics  and pharmacodynamics as well as the efficacy and safety of the active substance; the applicant's clinical overview  on  these  clinical  aspects  based  on  information  from  published  literature  was  considered sufficient. The bioequivalence study forms the pivotal basis with an open-label, randomised, two-treatment, twoperiod, two-sequence, single oral dose, crossover design. The study design was considered adequate to evaluate the bioequivalence of this formulation and was in line with the respective EU requirements. The choice of dose, sampling points, overall sampling times as well as wash-out period were adequate. The analytical method was validated. Pharmacokinetic and statistical methods applied were adequate. The test formulation of Pramipexole Accord met the protocol-defined criteria for bioequivalence when compared  with  Mirapexin  tablets.  The  point  estimates  and  their  90%  confidence  intervals  for  the parameters AUC0-t, AUC0- and Cmax were all contained within the protocol-defined acceptance range of 80.00 to 125.00%. Bioequivalence of the two formulations was demonstrated. A benefit/risk ratio comparable to the reference product can therefore be concluded. The  CHMP,  having  considered  the  data  submitted  in  the  application  and  available  on  the  chosen reference  medicinal  product,  is  of  the  opinion  that  no  additional  risk  minimisation  activities  are required beyond those included in the product information. 4. Recommendation Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription

## Conditions and requirements of the Marketing Authorisation

<!-- image -->

Pharmacovigilance System The  MAH  must  ensure  that  the  system  of  pharmacovigilance,  presented  in  Module  1.8.1  of  the marketing authorisation, is in place and functioning before and whilst the product is on the market. Risk Management System Not applicable PSUR cycle The  PSUR  cycle  for  the  product  will  follow  PSURs  submission  schedule  for  the  reference  medicinal product. Conditions or restrictions with regard to the safe and effective use of the medicinal product Not applicable. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States Not applicable. Medicinal product no longer authorised

Pramipexole Accord

Assessment report